HEATHER BEHANNA

Heather Behanna is a distinguished Principal at SR One, a prominent independent venture capital firm with a deep focus on the life sciences sector. In her pivotal role, Ms. Behanna is instrumental in identifying, evaluating, and nurturing early-stage companies poised to revolutionize healthcare. Her work at SR One primarily centers on investments in groundbreaking therapeutics, advanced diagnostics, and innovative medical devices, reflecting the firm's commitment to fostering scientific breakthroughs that address significant unmet medical needs.

Ms. Behanna's investment philosophy is deeply informed by her robust scientific background and extensive industry experience. She holds a PhD in Molecular Biology from Princeton University and completed postdoctoral research at Stanford University, providing her with a profound understanding of biological mechanisms and drug discovery processes. Prior to her tenure at SR One, Heather Behanna honed her expertise in drug discovery at Merck Research Laboratories, where she contributed to the development of novel pharmaceutical candidates. This hands-on experience in research and development gives her a unique perspective on the scientific rigor and potential of early-stage technologies.

Further enhancing her profile, Ms. Behanna also gained valuable experience in business development at Johnson & Johnson Innovation. This role equipped her with a keen insight into strategic partnerships, commercialization pathways, and the broader ecosystem of healthcare innovation. Her combined scientific acumen and business development savvy make her a highly effective investor, capable of assessing both the scientific merit and market potential of nascent companies.

At SR One, Heather Behanna plays a crucial role in shaping the firm's portfolio, which includes a diverse array of promising biotech and healthcare ventures. While specific individual investments are often a collaborative effort, her contributions are vital to the success of companies like T-Cypher Bio and Metaphore Biotechnologies, among others within SR One's robust portfolio. Her dedication to supporting visionary entrepreneurs and translating cutting-edge science into tangible patient benefits underscores her impact in the venture capital landscape. Through her strategic investments, Heather Behanna continues to advance the frontiers of life sciences, driving innovation that promises to improve global health outcomes.